Captrust Financial Advisors cut its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 137,133 shares of the company’s stock after selling 8,001 shares during the period. Captrust Financial Advisors’ holdings in AstraZeneca were worth $10,684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. boosted its holdings in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. purchased a new position in AstraZeneca during the second quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new position in AstraZeneca during the third quarter worth $28,000. Hobbs Group Advisors LLC purchased a new stake in AstraZeneca in the 2nd quarter valued at $35,000. Finally, Versant Capital Management Inc increased its stake in shares of AstraZeneca by 1,614.8% in the 2nd quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock worth $36,000 after acquiring an additional 436 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Stock Up 0.6 %
Shares of NASDAQ AZN opened at $67.62 on Monday. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The business’s 50 day moving average is $72.27 and its two-hundred day moving average is $77.44. The firm has a market cap of $209.66 billion, a price-to-earnings ratio of 32.35, a PEG ratio of 1.24 and a beta of 0.47. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.
Analyst Upgrades and Downgrades
AZN has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. TD Cowen raised their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.75.
Read Our Latest Report on AstraZeneca
AstraZeneca Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
- Five stocks we like better than AstraZeneca
- Airline Stocks – Top Airline Stocks to Buy Now
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- How to invest in marijuana stocks in 7 stepsĀ
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- What is a Secondary Public Offering? What Investors Need to Know
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.